In this observational study, a total of 980 patients underwent radiofrequency catheter ablation (RFCA) of symptomatic idiopathic VAs at the Guang-dong General Hospital between January 2012 and August 2014. All patients were refractory to one or two antiarrhythmic drugs. Structural heart disease was ruled out in all patients by means of transthoracic echocardiography, exercise stress test or coronary angiography (CAG) and cardiac magnetic resonance imaging in selected cases. Based on the successful ablation site, patients with VAs from the distal GCV, LCC or the subvalvular LVOT area were included in the present study. All patients provided written informed consent before the procedure, and the study was approved by the institutional review board of Guang-dong General Hospital.

The 12-lead ECGs were analyzed at a paper speed of 100 mm/s, and signals were amplified at 10 mm/mv. ECG analysis was focused on the following parameters: i. QRS morphology including bundle-branch block pattern and axis deviation; ii. QRS duration; iii. R wave amplitude in leads II and III; iv. R wave amplitude ratio in leads III to II (III/II); v. QS wave amplitude in leads aVL and aVR; vi. QS wave amplitude ratio in leads aVL to aVR (aVL/aVR); vii. The presence of pseudo-delta wave [12]; viii. Intrinsicoid deflection time (IDT) defined as the interval measured from the earliest ventricular activation to the peak of the R wave in V2; ix. Maximum deflection index (MDI) defined as the interval measured from the beginning of the QRS complex to the maximum deflection in the precordial leads divided by the QRS duration [1]; and ix. The presence of a notch at downslope of an initial q wave resembling a “w” pattern in lead I.

The electrophysiological study (EPS) was performed with the patients in a fasting non-sedated state. Antiarrhythmic drugs were discontinued for at least five half-lives prior to the study. A 3.5-mm tip irrigated ablation catheter (Navi-star, Biosense Webster, Diamond Bar, CA, USA, or Cool Path, IBI, St. Jude Medical, Irvine, CA, USA) compatible with a three-dimensional mapping system (CARTO3, Biosense Webster, Inc. or Ensite NavX Velocity, St. Jude Medical) was advanced via percutaneous access through a femoral artery to the aortic root and LVOT region for mapping and ablation. An additional long sheath was placed in the right femoral vein to access the coronary sinus (CS) for epicardial mapping and ablation, if necessary. A diagnostic catheter with 10 electrodes (Biosense Webster, Inc. or St. Jude Medical) was introduced into the CS as deeply as possible to map the GCV.

Activation times were measured from the onset of the earliest local bipolar electrogram to the earliest onset of the QRS complex in any of the 12 ECG leads. Pace mapping was additionally performed at the same site. If clinical arrhythmias failed to occur spontaneously, programmed ventricular stimulation was performed. If VAs were not inducible at baseline, intravenous isoproterenol infusion (2 to 5 μg/min) was administered to provoke clinical arrhythmias. Radiofrequency (RF) energy applications (30 W, temperature limit of 43°Cand irrigation rate of 17 ml/min) were stopped if the VAs did not terminate within 20 s. Ablation was not recommended to perform first in the GCV to avoid the risk of injury to coronary artery even the activation of CS catheter preceded the QRS onset by more than 20 ms. If ablation within the aortic cusps or endocardial at the LVOT failed to eliminate the VAs, then additional mapping was performed within the coronary venous system. If the earliest activation within the GCV preceded the QRS onset by more than 20 ms and pacing from that site produced an acceptable QRS match (> 11/12 leads), ablation within the GCV was attempted (Fig. 1). Prior to ablation within the GCV, CAG was performed to access the potential risk of coronary artery damage. RF energy applications were never delivered when the distance between the earliest activation site and an epicardial coronary artery was less than 5 mm. RF energy was applied at the earliest activation site in the GCV using an irrigated ablation catheter with a power of 20 W, temperature limit of 43 °C and an irrigation rate of 30 ml/min. The RF power was titrated to a maximal of 30 W. The end-point of the catheter ablation was the elimination and non-inducibility of VAs during an isoproterenol infusion and burst pacing from the right ventricle (to a cycle length as short as 300 ms). Following GCV ablation, CAG was repeated to ensure that there was no evidence of injury to the coronary artery. The site of origin of VAs was determined based on successful elimination with RF energy application.

After the procedure, continuous ECG monitoring was performed for 24 h. Antiarrhythmic drugs were discontinued in the absence of arrhythmia recurrence. Patients were evaluated every 3 months in an outpatient clinic. 24-h Holter monitoring was carried out in every visit. If patients report any chest discomfort symptoms must undergo treadmill exercise testing or event CAG again to eliminate the possibility of coronary artery damage.

Continuous variables (expressed as mean ± SD) were compared with Student t test (or Wilcoxon when necessary). Categorical variables were compared with chi-squared or Fisher exact test, as appropriate. A probability value < 0.05 was considered statistically significant.

The final population consisted of 39 patients (35 males, mean age 51 ± 23 years). Among these patients, 15 were successfully ablated at the distal GCV, 15 at the LCC and 9 at the subvalvular region (below the LCC). The baseline characteristics of the study cohort are depicted in Table 1. None of the patients displayed a family history of sudden cardiac death or a history of previous cardiovascular disease and decreased left ventricular ejection fraction. None of the patients had failed previous ablation procedures. The dominant arrhythmia was symptomatic VAs in all GCV group patients with high burden (23 ± 6%).

The ECG characteristics of VAs with to respect to successful site of ablation are shown in Table 1. All GCV VAs displayed a right bundle branch block (RBBB) pattern with inferior axis (Fig. 2). In particular, GCV VAs exhibited positive QRS forces in all precordial leads with no S waves in leads V5 and V6. An Rs pattern in leads V2-V4 was evident in all but two patients. VAs with a GCV origin exhibited more commonly a positive QRS complex concordance in all precordial leads, dominant negative waves in leads I and aVL, increased IDT, higher MDI and wider QRS duration (172 ± 19 ms) compared to LCC and subvalvular sites (p < 0.05). There were no significant differences of the (III/II) R wave amplitude ratio and the (aVL/aVR) QS wave amplitude ratio between GCV group and LCC or subvalvular groups (p > 0.05). A trend towards a higher (aVL/aVR) QS wave amplitude ratio was seen in VAs originating from the GCV compared to VAs arising from the LCC (1.72 ± 0.39 vs. 1.51 ± 0.2, p < 0.05).

A “w” pattern in lead I (Fig. 2) was present in 12 out of 15 (80%) VAs originating from the GCV compared to VAs arising from the other two sites (P < 0.01). An rS pattern in lead I was evident in the remaining 3 GCV patients. A QS or rS pattern in lead I was present in patients with LCC and endocardial LVOT origins.

Access to the left ventricle for mapping and ablation was performed retrogradely. Among the 15 patients with GCV VAs (Fig. 3), mapping and ablation of proceeded via right femoral vein in 13 patients at GCV and via the left subclavian vein in two patients. The targeted potential at the final ablation site preceded QRS complex onset of clinical VAs by 25 ± 5 ms (Figs. 3 and 4). Of these 15 patients, Pace mapping at the successful ablation site in GCV was obtained in only 10 patients.

During sinus rhythm, a clear atrial potential was always observed before the ventricular activation (Fig. 4). During VAs, a pre-potential was observed at the initial ventricular activation in 5 of 15 patients (33%). 12-lead ECG and local electrogram of successful ablation site in three representative cases of the distal GCV, LCC, and subvalvular LVOT were compared (Additional file 1: Figure S1). Mean time to clinical VAs disappearance was 6 ± 3 s. Among 15 patients with GCV VAs, impedance in the epicardium was much higher than LV endocardium (187 ± 9 Ω vs. 117 ± 9 Ω, P < 0.05). The VAs was successfully abolished with a mean of 2.3 ± 1.4 RF applications. No ST segment or T wave changes were observed during ablation in any of the 15 patients. Procedure time was 127 ± 57 min with fluoroscopy time of 12.3 ± 6.4 min. The distance between the successful ablation site in the GCV and the best (but failed) site in the endocardium was 14 ± 4 mm.

In the initial study population, 24 patients exhibited the earliest activation site at the distal GCV. Nine of these patients were excluded from the current analysis due to failure to advance the ablation catheter at the distal GCV (n = 4), failure to eliminate the VAs with RF applications (n = 3) and abandoned ablation because of the close proximity to a major coronary artery (n = 2). A schematic diagram shows the sites of origin of 15 GCV-VAs determined by the CAG of the left coronary artery and three-dimensional mapping (Additional file 2: Figure S2).

After an average of 36 ± 24 months follow up, 14 (93.3%) patients were free from VAs recurrence. No complications occurred immediately after the procedure or during follow up. None of the patients reported chest pain or discomfort symptoms at follow-up and therefore subsequent CAG was not repeated.

The main findings of the present study are the following: i. a “w” pattern in lead I distinguish a GCV origin from LCC or endocardial origins; ii. GCV VAs display an increased IDT and MDI compared to LCC or endocardial sites.

The ECG characteristics of VAs originating from the distal GCV varies. In the proximal segment, VAs display a RBBB morphology and in the distal segment as well in the anterior interventricular vein a LBBB morphology [2, 8, 11]. In our series, all cases displayed a RBBB, and therefore the proximal segment of distal GCV appears to be the accurate site of origin. Previous studies addressing the QRS morphology in lead I have demonstrated more commonly an rS and less commonly a QS pattern [2, 8, 11].

In this study, the presence of a notch at downslope of the initial q wave resembling a “w” pattern in lead I was present in 80% of VAs originating from the distal GCV compared to none of VAs arising from the LCC and the endocardial LVOT areas. GCV VAs are mostly located at epicardium of superior-lateral LV. The presence of initial negative forces (q wave) in lead I is indicative of an initial rightward activation of the LV base from an epicardial origin. VAs originating from the epicardium showed a q wave in lead I as initial activation which means that the net vector of the global activation pattern from left to right and superior to inferior [13]. The presence of a q wave in lead I and absence of q waves in the inferior leads appear to be a very sensitive criterion for identifying an epicardial site of origin [13]. Therefore, a “w” pattern in lead I raises a high degree of suspicion for a distal GCV origin.

A trend towards a higher (aVL/aVR) QS wave amplitude ratio was seen in VAs originating from the GCV compared to VAs arising from the LCC, which is consistent with previous findings [8]. Finally, we showed that distal GCV VAs display an increased MDI and IDT compared to LCC or endocardial sites. A MDI > 0.59 has been previously shown to identify VAs of an epicardial origin [1, 13]. In our study, all patients had a MDI > 0.60 (100% sensitivity). Previous reports with VAs arising from the distal GCV have consistently demonstrated a higher MDI in relation to endocardial sites [2, 14]. Li et al. have demonstrated that pseudo wave time and IDT were significantly longer for VAs of distal GCV origin compared to VAs from the cusps or the endocardium [14].

In our study, catheter ablation of VAs arising from the distal GCV was highly effective, in the cases where RF applications could be successfully delivered. However, catheter ablation of VAs arising from the distal GCV is challenging. We showed that in a significant number of patients (9/24) certain limitations do not allow catheter ablation. First, it is not always possible to advance the ablation catheter to the distal GCV. Second, the high impedance and/or the limited cooling from the blood flow may lead to ineffective RF applications. Third, the close proximity to the coronary arteries does not permit a safe ablation procedure. Nagashima et al. reported occlusion requiring stenting of a marginal branch of the circumflex artery in 2 who received RF energy at sites 2 mm and 5–7 mm distant from the vessel, respectively [11]. A distance of 5–12 mm between the ablation catheter and the coronary artery may reduce the risk of injury[15].

VAs displayed a RBBB morphology with inferior axis could safely be eliminated in the GCV, but sometimes ablation can be challenging because of the close proximity to the coronary arteries and failure to advance the ablation catheter at the distal GCV. RFCA within GCV may be limited by a high impedance. Potential risks (Coronary vasospasm, coronary artery damage or perforation) of ablation within the GCV are much more than in the endocardium. Repeated CAG and careful titration of irrigated radiofrequency energy for successful ablation without acute complications. Even no complications were reported in this study, we recommend catheter ablation performed within the distal of GCV with strong clinical indications including symptomatic high burden VAs, arrhythmia induced cardiomyopathy and special profession such as pilot and sports athletes. Besides, catheter ablation was performed in the GCV only after attempting to eliminate the VAs in the endocardium has failed.

A few cases of GCV VAs might be eliminated through LVOT endocardium ablation. Because the breakout site of GCV VAs maybe located adjacent LV epicardium, but the true origin maybe located adjacent LV endocardium. So these VAs originating from the GCV could be ablated from the LCC/adjacent LV endocardium. We could not determine the true origin site of the VAs even after they were eliminated. As a result, the site of origin of VAs was determined based on successful elimination in our study.

This is a single-center observational and retrospectively study including a small number of patients with relatively uncommon VAs. Although none of the patients reported symptoms during follow-up, coronary artery damage in terms of stenosis cannot be excluded. Due to the signal interference of our catheter labs, the unipolar electrogram was very difficult to identify during mapping and ablation, so the data about unipolar electrogram was not available in this study.